Key Takeaways
- • Lighthouse Pharmaceuticals, a Novato-based dementia drug startup, secured $12 million in venture funding led by Boston-based Double Point Ventures, with Marin Sonoma Impact Ventures contributing $500,000 as part of its first medical biotech investment.
- • The National Institute on Aging awarded Lighthouse a $49.2 million grant to fund a nationwide clinical trial involving 300 patients across 40 sites, testing a drug targeting P. gingivalis bacteria linked to gum disease and Alzheimer's cognitive decline.
- • Lighthouse estimates that up to 40% of people with mild to moderate Alzheimer's disease may carry P. gingivalis; the trial will assess whether targeting this bacteria can slow or halt cognitive decline in this patient population.
- • Marin Sonoma Impact Ventures has backed 20 North Bay startups since its 2021 founding, with Lighthouse Pharmaceuticals representing its first entry into medical biotech, signaling an expansion of the regional fund's investment strategy.
- • The research targets a novel mechanism linking bacterial infection to neurodegeneration, building on preclinical evidence that P. gingivalis infection in animal models causes cognitive impairment in memory centers of the brain.
Summary
Lighthouse Pharmaceuticals, a dementia-focused biotech startup based in Novato at the Buck Institute for Research on Aging, has completed a $12 million Series funding round led by Boston venture capital firm Double Point Ventures. Marin Sonoma Impact Ventures, a regional fund focused on North Bay entrepreneurship, participated in the round with a $500,000 investment—marking its first foray into medical biotech after backing 20 other startups since 2021.
The company, co-founded and led by CEO Casey Lynch of Sonoma, is advancing a novel therapeutic approach targeting P. gingivalis, a bacterium associated with periodontal disease and increasingly linked to Alzheimer's disease pathology. Based on earlier clinical evidence, Lynch estimates that approximately 40% of patients with mild to moderate Alzheimer's disease carry this pathogen. The scientific premise rests on emerging research indicating that bacterial infections can trigger neurological disease; animal models have demonstrated that oral P. gingivalis infection crosses into the brain and induces cognitive impairment and neurodegeneration in memory-critical regions.
The funding round coincides with a significant non-dilutive capital achievement: the National Institute on Aging, part of the National Institutes of Health, awarded Lighthouse a $49.2 million grant to conduct a nationwide clinical trial examining whether a drug targeting P. gingivalis can slow or stabilize cognitive decline in patients with mild to moderate Alzheimer's disease. The trial will enroll 300 patients across 40 clinical sites, providing a rigorous test of this bacterial-neurological hypothesis in a large patient population.
Zachary Kushel, founder and managing partner of Marin Sonoma Impact Ventures, announced the investment at the firm's annual gathering in May at the College of Marin, underscoring the regional venture ecosystem's growing engagement with life sciences innovation. The combination of venture backing and substantial federal grant funding positions Lighthouse to advance a mechanistically distinct approach to Alzheimer's therapeutic intervention, potentially opening a new drug development pathway for cognitive disease.
The company, co-founded and led by CEO Casey Lynch of Sonoma, is advancing a novel therapeutic approach targeting P. gingivalis, a bacterium associated with periodontal disease and increasingly linked to Alzheimer's disease pathology. Based on earlier clinical evidence, Lynch estimates that approximately 40% of patients with mild to moderate Alzheimer's disease carry this pathogen. The scientific premise rests on emerging research indicating that bacterial infections can trigger neurological disease; animal models have demonstrated that oral P. gingivalis infection crosses into the brain and induces cognitive impairment and neurodegeneration in memory-critical regions.
The funding round coincides with a significant non-dilutive capital achievement: the National Institute on Aging, part of the National Institutes of Health, awarded Lighthouse a $49.2 million grant to conduct a nationwide clinical trial examining whether a drug targeting P. gingivalis can slow or stabilize cognitive decline in patients with mild to moderate Alzheimer's disease. The trial will enroll 300 patients across 40 clinical sites, providing a rigorous test of this bacterial-neurological hypothesis in a large patient population.
Zachary Kushel, founder and managing partner of Marin Sonoma Impact Ventures, announced the investment at the firm's annual gathering in May at the College of Marin, underscoring the regional venture ecosystem's growing engagement with life sciences innovation. The combination of venture backing and substantial federal grant funding positions Lighthouse to advance a mechanistically distinct approach to Alzheimer's therapeutic intervention, potentially opening a new drug development pathway for cognitive disease.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.